,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,lastDividendValue,lastDividendDate,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Dr. Vishwas  Seshadri M.B.A., Ph.D.', 'age': 46, 'title': 'Pres, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 1021800, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
1,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Mr. Joseph Walter Vazzano CPA', 'age': 38, 'title': 'Chief Financial Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 655168, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
2,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': ""Dr. Brendan M. O'Malley J.D., Ph.D."", 'age': 53, 'title': 'Sr. VP & Gen. Counsel', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 699135, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
3,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Mr. Brian  Kevany Ph.D.', 'title': 'VP, CTO & Head of Research', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
4,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Mr. Gregory  Gin', 'title': 'VP of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
5,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Ms. Alison  Hardgrove', 'title': 'VP of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
6,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Mr. Jon  Voss', 'age': 62, 'title': 'VP & Head of Quality', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
7,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Mr. Dmitriy  Grachev M.D., Ph.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
8,1330 Avenue of the Americas,33rd Floor,New York,NY,10019,United States,646 813 4701,https://www.abeonatherapeutics.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.",57,"{'maxAge': 1, 'name': 'Dr. Madhav  Vasanthavada M.B.A., Ph.D.', 'title': 'Chief Commercial Officer & Head of Bus. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,4.1,4.06,3.905,4.176,4.1,4.06,3.905,4.176,0.0,1.279391,-2.0561225,97944,97944,146185,100150,100150,3.87,4.06,800,800,99766280,2.19,5.8,27.961401,3.7446,3.2467,0.0,0.0,USD,68968168,0.0,18630280,24755900,500539,538035,1690761600,1693440000,0.0202,0.06729,0.43665,4.12,0.0223,24755900,0.435,9.264368,1672444800,1703980800,1688083200,-39316000,-1.82,-1.96,1:25,1656979200,19.33,-1.633,0.044041395,0.14113986,3706.25,954460800,NCM,EQUITY,ABEO,ABEO,Abeona Therapeutics Inc.,Abeona Therapeutics Inc.,338218200,America/New_York,EDT,6a7dfae4-c578-3526-bdcd-a5a90d9256dd,finmb_360935,-14400000,4.03,38.0,8.0,20.5,18.0,1.7,buy,4,36772000,1.485,-42238000,5974000,4.502,4.665,3568000,63.927,0.261,-0.5727,-2.67174,-28001000,-22881250,-42811000,2.5,0.0,0.0,-12.618549,USD,
